Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

Published:2020-01 Issue:1 Volume:21 Page:44-59
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Schmid Peter,Rugo Hope S,Adams Sylvia,Schneeweiss Andreas,Barrios Carlos H,Iwata Hiroji,Diéras Véronique,Henschel Volkmar,Molinero Luciana,Chui Stephen Y,Maiya Vidya,Husain Amreen,Winer Eric P,Loi Sherene,Emens Leisha A

Publisher

Elsevier BV

Subject

Oncology

Reference22 articles.

1. Measures of outcome in metastatic breast cancer: insights from a real-world scenario;Bonotto;Oncologist,2014

2. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer;Schmid;N Engl J Med,2018

3. 4th ESO-ESMO International consensus guidelines for advanced breast cancer (ABC 4);Cardoso;Ann Oncol,2018

4. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Senkus;Ann Oncol,2015

5. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial;Tutt;Nat Med,2018

Cited by 910 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ALG3 predicts poor prognosis and increases resistance to anti-PD-1 therapy through modulating PD-L1 N-link glycosylation in TNBC;International Immunopharmacology;2024-10

2. PD-L1 expression and tumor-infiltrating lymphocytes: Correlations and prognostic values in Chinese triple-negative breast cancer patients with different molecular subtyping;Pathology - Research and Practice;2024-10

3. Tumour immune characterisation of primary triple-negative breast cancer using automated image quantification of immunohistochemistry-stained immune cells;Scientific Reports;2024-09-13

4. AI-powered omics-based drug pair discovery for pyroptosis therapy targeting triple-negative breast cancer;Nature Communications;2024-08-30

5. Synergizing Immunotherapy and Antibody–Drug Conjugates: New Horizons in Breast Cancer Therapy;Pharmaceutics;2024-08-29